U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07831187) titled 'Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence' on Sept. 15.
Brief Summary: This investigator-initiated, multicenter clinical trial will evaluate the safety and preliminary effectiveness of adding entacapone to bevacizumab in adults with isocitrate dehydrogenase (IDH)-wildtype glioblastoma at first recurrence after standard first-line treatment. Participants must not have previously received bevacizumab. A multidisciplinary neuro-oncology team must determine that repeat tumor resection is not appropriate, or the patient must decline repeat surgery after being informed of its potential benefits and risks.
The stud...